Face taping promises smoother skin and fewer wrinkles without injectables, but evidence suggests any visible benefits are largely temporary.
News|Articles|July 4, 2024
Q&A: Mona Shahriari, MD, FAAD, Talks Multidisciplinary Care
Shahriari spoke about the importance of comprehensive care, collaborating with other specialists, and addressing psychosocial impact.
Advertisement
Reference
Hebebrand M. Poll: Which specialties have you referred patients to, ensuring they receive multidisciplinary care surrounding their skin condition? Dermatology Times. June 5, 2024. Accessed July 2, 2024.
Advertisement
Related to this article
Castor oil has become a popular social media remedy for thicker, longer hair, but evidence supporting its ability to stimulate hair growth remains limited.
Can “Botox in a bottle” really rival injectable neuromodulators? We examine the evidence behind topical peptide serums and Argireline.
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
Advertisement
Advertisement
Trending on Dermatology Times
1
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
2
ORKA-001 Achieves 61% Complete Skin Clearance in Psoriasis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
Biologics, JAK Inhibitors, and Atopic March Data in Pediatric Atopic Dermatitis
5